Cargando…

A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms

Objective. To compare the efficacy of low-dose COC containing desogestrel (DSG) with drospirenone (DRSP) in the changes of premenstrual symptoms. Methods. In an open-label randomized controlled trial, 90 women with premenstrual syndrome who required COC were randomly recruited and allocated equally...

Descripción completa

Detalles Bibliográficos
Autores principales: Wichianpitaya, Jirath, Taneepanichskul, Surasak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609439/
https://www.ncbi.nlm.nih.gov/pubmed/23577032
http://dx.doi.org/10.1155/2013/487143
_version_ 1782264316765929472
author Wichianpitaya, Jirath
Taneepanichskul, Surasak
author_facet Wichianpitaya, Jirath
Taneepanichskul, Surasak
author_sort Wichianpitaya, Jirath
collection PubMed
description Objective. To compare the efficacy of low-dose COC containing desogestrel (DSG) with drospirenone (DRSP) in the changes of premenstrual symptoms. Methods. In an open-label randomized controlled trial, 90 women with premenstrual syndrome who required COC were randomly recruited and allocated equally to receive either 6 cycles of 20 micrograms ethinyl estradiol (EE)/150 micrograms DSG (DSG group) or 20 micrograms EE/3 mg DRSP (DRSP group) in 24/4 extended regimen. Analysis of covariance and repeated analysis of variance were used to determine the difference of mean Women's Health Assessment Questionnaire (WHAQ) scores changes between groups, within group, and in premenstrual, menstrual, and postmenstrual phases. Results. Baseline characteristics and WHAQ scores were comparable. At the ends of the 3rd and the 6th cycles, mean WHAQ scores of all the 3 phases in DRSP group showed significant reduction and were significantly lower than those in DSG group. DSG group showed significant reduction in both premenstrual and menstrual phases after the 6th cycle. Adverse effects were comparable in both groups. In conclusion, low-dose COC containing either DSG or DRSP reduced premenstrual symptoms, but the latter showed greater efficacy and earlier reduction.
format Online
Article
Text
id pubmed-3609439
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36094392013-04-10 A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms Wichianpitaya, Jirath Taneepanichskul, Surasak Obstet Gynecol Int Clinical Study Objective. To compare the efficacy of low-dose COC containing desogestrel (DSG) with drospirenone (DRSP) in the changes of premenstrual symptoms. Methods. In an open-label randomized controlled trial, 90 women with premenstrual syndrome who required COC were randomly recruited and allocated equally to receive either 6 cycles of 20 micrograms ethinyl estradiol (EE)/150 micrograms DSG (DSG group) or 20 micrograms EE/3 mg DRSP (DRSP group) in 24/4 extended regimen. Analysis of covariance and repeated analysis of variance were used to determine the difference of mean Women's Health Assessment Questionnaire (WHAQ) scores changes between groups, within group, and in premenstrual, menstrual, and postmenstrual phases. Results. Baseline characteristics and WHAQ scores were comparable. At the ends of the 3rd and the 6th cycles, mean WHAQ scores of all the 3 phases in DRSP group showed significant reduction and were significantly lower than those in DSG group. DSG group showed significant reduction in both premenstrual and menstrual phases after the 6th cycle. Adverse effects were comparable in both groups. In conclusion, low-dose COC containing either DSG or DRSP reduced premenstrual symptoms, but the latter showed greater efficacy and earlier reduction. Hindawi Publishing Corporation 2013 2013-02-20 /pmc/articles/PMC3609439/ /pubmed/23577032 http://dx.doi.org/10.1155/2013/487143 Text en Copyright © 2013 J. Wichianpitaya and S. Taneepanichskul. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Wichianpitaya, Jirath
Taneepanichskul, Surasak
A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms
title A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms
title_full A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms
title_fullStr A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms
title_full_unstemmed A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms
title_short A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms
title_sort comparative efficacy of low-dose combined oral contraceptives containing desogestrel and drospirenone in premenstrual symptoms
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609439/
https://www.ncbi.nlm.nih.gov/pubmed/23577032
http://dx.doi.org/10.1155/2013/487143
work_keys_str_mv AT wichianpitayajirath acomparativeefficacyoflowdosecombinedoralcontraceptivescontainingdesogestrelanddrospirenoneinpremenstrualsymptoms
AT taneepanichskulsurasak acomparativeefficacyoflowdosecombinedoralcontraceptivescontainingdesogestrelanddrospirenoneinpremenstrualsymptoms
AT wichianpitayajirath comparativeefficacyoflowdosecombinedoralcontraceptivescontainingdesogestrelanddrospirenoneinpremenstrualsymptoms
AT taneepanichskulsurasak comparativeefficacyoflowdosecombinedoralcontraceptivescontainingdesogestrelanddrospirenoneinpremenstrualsymptoms